AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19528806 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute autologous blood transfusion with acute normovolemic haemodilution (group A)
Number of subjects: 62
Study 19528806 — intervention group
Group type: COMPARATOR
Intervention: Homologous blood transfusion (group H)
Number of subjects: 62
Study 19528806 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and H)
Number of subjects: 62
Study 16741259 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial body potassium (PBK) measurement system
Number of subjects: 0
Study 16741259 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography and magnetic resonance imaging
Number of subjects: 0
Study 15252704 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 51
Study 15252704 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 51
Study 15252704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 11716371 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-bearing total knee prosthesis (AMK)
Number of subjects: 116
Study 11716371 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing total knee prosthesis (LCS)
Number of subjects: 116
Study 9143001 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal CRH (20 micrograms every 10 min)
Number of subjects: 11
Study 9143001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9143001 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal CRH
Number of subjects: 11
Study 7802851 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (5 mg daily)
Number of subjects: 154
Study 7802851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 3314832 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (mean dose 6.7 mg)
Number of subjects: 0
Study 3314832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31954014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual task training (Group A)
Number of subjects: 64
Study 31954014 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (Group B)
Number of subjects: 64
Study 31004420 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV SIGH
Number of subjects: 14
Study 31004420 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 14
Study 31004420 — intervention group
Group type: COMPARATOR
Intervention: PSV
Number of subjects: 14
Study 31004420 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV SIGH and NAVA
Number of subjects: 14
Study 29211727 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-platform video game training (Super Mario 64) for 6 months
Number of subjects: 33
Study 29211727 — intervention group
Group type: COMPARATOR
Intervention: Active control (self-directed computerized music lessons)
Number of subjects: 33
Study 29211727 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-platform video game training (Super Mario 64)
Number of subjects: 33
Study 29211727 — intervention group
Group type: COMPARATOR
Intervention: No intervention (no-contact control group)
Number of subjects: 33
Study 26593888 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program provided by a nurse
Number of subjects: 96
Study 26593888 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 96
Study 23480324 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (10 or 30 mg/day)
Number of subjects: 296
Study 23480324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 21950194 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin adjusted to maintain INR between 1.5 and 1.9 (Group A)
Number of subjects: 39
Study 21950194 — intervention group
Group type: COMPARATOR
Intervention: Warfarin adjusted to maintain INR between 2 and 3 (Group B)
Number of subjects: 39
Study 18422823 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation support offered by letter and referral to NHS stop smoking services
Number of subjects: 6856
Study 16939033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonium hexafluorosilicate (SiF)
Number of subjects: 0
Study 16939033 — intervention group
Group type: COMPARATOR
Intervention: Diamine silver fluoride (AgF)
Number of subjects: 0
Study 14575972 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 36
Study 14575972 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 36
Study 10959618 — intervention group
Group type: EXPERIMENTAL
Intervention: Active absorbable algal calcium (AAA Ca)
Number of subjects: 9
Study 10959618 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3)
Number of subjects: 9
Study 10959618 — intervention group
Group type: COMPARATOR
Intervention: Non‐calcium‐containing placebo (C)
Number of subjects: 9
Study 9495931 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable collagen membrane in guided tissue regeneration (GTR) therapy
Number of subjects: 12
Study 9495931 — intervention group
Group type: COMPARATOR
Intervention: Surgical flap debridement only (Control)
Number of subjects: 12
Study 9495931 — intervention group
Group type: COMPARATOR
Intervention: Unoperated control sites
Number of subjects: 12
Study 8454791 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin testing with major and minor determinants of benzylpenicillin and minor determinant mixtures of ampicillin, amoxicillin, or cloxacillin
Number of subjects: 112
Study 8454791 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin testing with semisynthetic penicillin reagents derived from ampicillin, amoxicillin, or cloxacillin
Number of subjects: 112
Study 8454791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin and amoxicillin
Number of subjects: 112
Study 8454791 — intervention group
Group type: COMPARATOR
Intervention: Benzylpenicillin derivatives
Number of subjects: 112
Study 8454791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 112
Study 8454791 — intervention group
Group type: COMPARATOR
Intervention: Benzylpenicillin
Number of subjects: 112
Study 3755683 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine with 1 g sucralfate
Number of subjects: 12
Study 3755683 — intervention group
Group type: COMPARATOR
Intervention: 200 mg cimetidine with water
Number of subjects: 12
Study 29388909 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated messaging reminders
Number of subjects: 95
Study 29388909 — intervention group
Group type: COMPARATOR
Intervention: No automated messaging reminders (Control)
Number of subjects: 95
Study 27575713 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 110
Study 27575713 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 110
Study 24342386 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMT + CBT
Number of subjects: 63
Study 24342386 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMT placebo + CBT
Number of subjects: 63
Study 24342386 — intervention group
Group type: COMPARATOR
Intervention: CBT-alone
Number of subjects: 63
Study 24342386 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ABMT
Number of subjects: 63
Study 24342386 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 63
Study 22797552 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 132
Study 22797552 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 132
Study 22797552 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine and Fenoterol
Number of subjects: 132
Study 20211022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2 on day 1 of a 21-day cycle) plus best supportive care (BSC)
Number of subjects: 900
Study 20211022 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 900
Study 17372737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (2.5 mg)
Number of subjects: 40
Study 16376755 — intervention group
Group type: EXPERIMENTAL
Intervention: H/D amount less than 2 kg (group 1)
Number of subjects: 81
Study 16376755 — intervention group
Group type: EXPERIMENTAL
Intervention: H/D amount between 2 and 3 kg (group 2)
Number of subjects: 81
Study 16376755 — intervention group
Group type: EXPERIMENTAL
Intervention: H/D amount larger than 3 kg (group 3)
Number of subjects: 81
Study 12421100 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (simvastatin, pravastatin, fluvastatin, lovastatin)
Number of subjects: 19
Study 12421100 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 19
Study 9797791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (200 mg every 8 hours)
Number of subjects: 22
Study 9797791 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg every 12 hours)
Number of subjects: 22
Study 9797791 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir and clarithromycin in combination
Number of subjects: 22
Study 8044016 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM‐WM therapy (oral administration and external treatment of TCM plus wet-compressing with antibiotics)
Number of subjects: 34
Study 8044016 — intervention group
Group type: COMPARATOR
Intervention: WM therapy (Western medicine therapy including pain-killer, antibiotics, debridement and dressing change)
Number of subjects: 34
Study 2698935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dietary advice
Number of subjects: 141
Study 2698935 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 141
Study 1090718 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cephaloridine (25 mg/kg every 6 hr for 48 hr)
Number of subjects: 69
Study 1090718 — intervention group
Group type: COMPARATOR
Intervention: Systemic injection of cephaloridine
Number of subjects: 69
Study 31208499 — intervention group
Group type: EXPERIMENTAL
Intervention: Early short-term upgrade therapy (ICS/LABA inhaled every morning for 7-10 days)
Number of subjects: 100
Study 27761000 — intervention group
Group type: EXPERIMENTAL
Intervention: T80/A5/H12.5 (telmisartan 80 mg/amlodipine 5 mg plus hydrochlorothiazide 12.5 mg)
Number of subjects: 309
Study 27761000 — intervention group
Group type: COMPARATOR
Intervention: T80/A5 (telmisartan 80 mg/amlodipine 5 mg)
Number of subjects: 309
Study 27761000 — intervention group
Group type: EXPERIMENTAL
Intervention: T80/A5/H12.5
Number of subjects: 309
Study 27761000 — intervention group
Group type: COMPARATOR
Intervention: T80/A5
Number of subjects: 309
Study 27005658 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol supplementation (75 mg twice daily)
Number of subjects: 0
Study 27005658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25226015 — intervention group
Group type: COMPARATOR
Intervention: Tavaborole 2.5%
Number of subjects: 336
Study 25226015 — intervention group
Group type: COMPARATOR
Intervention: Tavaborole 5.0%
Number of subjects: 336
Study 25226015 — intervention group
Group type: COMPARATOR
Intervention: Tavaborole 7.5%
Number of subjects: 336
Study 25226015 — intervention group
Group type: EXPERIMENTAL
Intervention: Tavaborole 5.0% (cohort 3 of study 2)
Number of subjects: 336
Study 25226015 — intervention group
Group type: COMPARATOR
Intervention: Tavaborole 2.5%, 5.0%, and 7.5%
Number of subjects: 336
Study 21916994 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-guidewire (DG) technique
Number of subjects: 44
Study 21916994 — intervention group
Group type: COMPARATOR
Intervention: Precut sphincterotomy (PS) technique
Number of subjects: 44
Study 20808251 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1 μg/kg bolus)
Number of subjects: 42
Study 20808251 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 μg/kg bolus)
Number of subjects: 42
Study 17295579 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional treatment foster care (MTFC)
Number of subjects: 81
Study 17295579 — intervention group
Group type: COMPARATOR
Intervention: Group care
Number of subjects: 81
Study 16228834 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice condition (patients could choose to watch the video)
Number of subjects: 166
Study 16228834 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching the video (intervention)
Number of subjects: 166
Study 16228834 — intervention group
Group type: COMPARATOR
Intervention: No choice condition (patients had no choice to watch the video)
Number of subjects: 166
Study 11901038 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5‐FGF4
Number of subjects: 79
Study 11901038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 10215753 — intervention group
Group type: EXPERIMENTAL
Intervention: Alniditan 2 mg
Number of subjects: 27
Study 10215753 — intervention group
Group type: EXPERIMENTAL
Intervention: Alniditan 4 mg
Number of subjects: 27
Study 7838899 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (Clon), 150 micrograms IV
Number of subjects: 12
Study 7838899 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 1900396 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane with O2 (n = 6)
Number of subjects: 12
Study 1900396 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane with O2 and 60% N2O (n = 6)
Number of subjects: 12
Study 6339289 — intervention group
Group type: EXPERIMENTAL
Intervention: Halometasone ointment (0.05%)
Number of subjects: 182
Study 6339289 — intervention group
Group type: COMPARATOR
Intervention: Fluocortolone + fluocortolone caproate ointment (0.25% each)
Number of subjects: 182
Study 31696724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully Covered Self-Expandable Biliary Metal Stents (FCSEBMS) placed prophylactically in 15 patients
Number of subjects: 22
Study 31696724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully Covered Self-Expandable Biliary Metal Stents (FCSEBMS) placed for treatment of refractory bleed in 7 patients
Number of subjects: 22
Study 31696724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully Covered Self-Expandable Biliary Metal Stents (FCSEBMS)
Number of subjects: 22
Study 30106880 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (200 mg/d)
Number of subjects: 69
Study 30106880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 27169685 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphacalcidol 1 μg daily for 6 months
Number of subjects: 178
Study 27169685 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol 1 000 IU daily for 6 months
Number of subjects: 178
Study 26431365 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) during visual scanning training
Number of subjects: 29
Study 26431365 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS during visual scanning training
Number of subjects: 29
Study 23359516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 23359516 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg QD with lead-in (LI)
Number of subjects: 429
Study 23359516 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD with lead-in (LI)
Number of subjects: 429
Study 23359516 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD
Number of subjects: 429
Study 23359516 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD in mRVR patients
Number of subjects: 429
Study 23359516 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD in GT-1a patients
Number of subjects: 429
Study 23359516 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg QD/LI
Number of subjects: 429
Study 23359516 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg QD/LI
Number of subjects: 429
Study 22586900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergoferon
Number of subjects: 0
Study 19843000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (20 mg three times daily, increased to 40 mg and 80 mg tid)
Number of subjects: 35
Study 19843000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 19843000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (20 mg, 40 mg, and 80 mg tid)
Number of subjects: 35
Study 16894098 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 16894098 — intervention group
Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 0
Study 14984383 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day)
Number of subjects: 129
Study 14984383 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (low-dose)
Number of subjects: 129
Study 12539684 — intervention group
Group type: EXPERIMENTAL
Intervention: Millimeter wave treatment (7.1 mm, 43 GHz, 10 mW/cm2)
Number of subjects: 30
Study 12539684 — intervention group
Group type: EXPERIMENTAL
Intervention: Millimeter wave treatment
Number of subjects: 30
Study 12539684 — intervention group
Group type: COMPARATOR
Intervention: Control group (soothing treatment)
Number of subjects: 30
Study 9018645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oxytocin (2 mU/min, increased by 2 mU/min at 30-minute intervals) started immediately after PGE2 placement
Number of subjects: 50
Study 9018645 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oxytocin (2 mU/min, increased by 2 mU/min at 30-minute intervals) started six hours after PGE2 placement
Number of subjects: 50
Study 7887039 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable instruments
Number of subjects: 158
Study 7887039 — intervention group
Group type: COMPARATOR
Intervention: Disposable instruments
Number of subjects: 158
Study 2196372 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 200 mg
Number of subjects: 18
Study 2196372 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 400 mg
Number of subjects: 18
Study 2196372 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 18
Study 2196372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2196372 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 18
Study 87314 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse brain stimulation (DBS) for 20 minutes before sleep onset
Number of subjects: 16
Study 30303427 — intervention group
Group type: EXPERIMENTAL
Intervention: FS Grifols
Number of subjects: 224
Study 30303427 — intervention group
Group type: COMPARATOR
Intervention: Surgicel®
Number of subjects: 224
Study 31082818 — intervention group
Group type: EXPERIMENTAL
Intervention: Total contact cast and a skin substitute (human amniotic allograft)
Number of subjects: 13
Study 31082818 — intervention group
Group type: COMPARATOR
Intervention: Total contact cast and standard wound care
Number of subjects: 13
Study 25599319 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Gel Supernatant (PGS) plus supportive medical treatment
Number of subjects: 80
Study 25599319 — intervention group
Group type: COMPARATOR
Intervention: Supportive medical treatment alone
Number of subjects: 80
Study 26214609 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Persian medical schemes and recommendations
Number of subjects: 100
Study 26214609 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 100
Study 23007693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapeutic counseling
Number of subjects: 160
Study 23007693 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 160
Study 21303505 — intervention group
Group type: EXPERIMENTAL
Intervention: Loozit® group intervention
Number of subjects: 151
Study 19342442 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg/d folic acid (FA) for 8 weeks, then discontinued for 12 weeks
Number of subjects: 27
Study 19342442 — intervention group
Group type: COMPARATOR
Intervention: No supplements (Control group)
Number of subjects: 27
Study 16650363 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin for 8 weeks
Number of subjects: 30
Study 16650363 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 30
Study 17152306 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing-to-learn (WTL) strategy
Number of subjects: 87
Study 17152306 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 87
Study 11714895 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate 5 mg/70 kg, i.v. at various infusion rates (2 min bolus, 15 min, 60 min)
Number of subjects: 0
Study 11714895 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate 10 mg/70 kg, i.v. at various infusion rates (2 min bolus, 15 min, 60 min)
Number of subjects: 0
Study 11714895 — intervention group
Group type: COMPARATOR
Intervention: Placebo 0 mg/70 kg, i.v. at various infusion rates (2 min bolus, 15 min, 60 min)
Number of subjects: 0
Study 11714895 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster infusion rates of morphine
Number of subjects: 0
Study 11714895 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (both doses)
Number of subjects: 0
Study 9137028 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour heparin flushing interval
Number of subjects: 83
Study 9137028 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour heparin flushing interval
Number of subjects: 83
Study 9137028 — intervention group
Group type: COMPARATOR
Intervention: 4-hour heparin flushing interval
Number of subjects: 83
Study 9137028 — intervention group
Group type: COMPARATOR
Intervention: 22-gauge catheters
Number of subjects: 83
Study 9137028 — intervention group
Group type: COMPARATOR
Intervention: 24-gauge catheters
Number of subjects: 83
Study 9137028 — intervention group
Group type: EXPERIMENTAL
Intervention: Age differences in catheter longevity
Number of subjects: 83
Study 8181019 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (ACE-I)
Number of subjects: 0
Study 8181019 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone antagonists or alternative RAAS blockers (renin inhibitors or angiotensin II receptor blocking agents)
Number of subjects: 0
Study 2142116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular etofenamate
Number of subjects: 96
Study 2142116 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular diclofenac sodium
Number of subjects: 96